Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
165 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape. Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 12, 7, 10 and 2 respectively. Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 6 Global Markets Direct Report Coverage 6 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 7 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Products under Development by Companies 12 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 14 Assessment by Target 14 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 22 AnGes MG Inc 22 AstraZeneca Plc 22 Athera Biotechnologies AB 23 Athersys Inc 23 Bayer AG 24 Betagenon AB 24 BiogenCell Ltd 25 CardioVascular BioTherapeutics Inc 25 Celgene Corp 26 Diffusion Pharmaceuticals Inc 26 Foresee Pharmaceuticals LLC 27 Hemostemix Ltd 27 ID Pharma Co Ltd 28 Juventas Therapeutics Inc 28 LipimetiX Development Inc 29 miRagen Therapeutics Inc 29 Novartis AG 30 Nuo Therapeutics Inc 30 Proteon Therapeutics Inc 31 Recardio GmbH 31 Resverlogix Corp 32 Sigma-Tau SpA 32 Stemedica Cell Technologies Inc 33 Theravasc Inc 33 VESSL Therapeutics Ltd 34 ViroMed Co Ltd 34 Yuyu Pharma Inc 35 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles 36 ACP-01 - Drug Profile 36 AEM-28 - Drug Profile 39 ALD-301 - Drug Profile 41 alprostadil - Drug Profile 44 apabetalone - Drug Profile 46 BAY-1193397 - Drug Profile 58 beperminogene perplasmid - Drug Profile 59 BGC-101 - Drug Profile 64 canakinumab - Drug Profile 65 CVBT-141C - Drug Profile 71 DVC-10101 - Drug Profile 72 ELS-140 - Drug Profile 73 FP-045 - Drug Profile 74 JVS-100 - Drug Profile 75 levocarnitine propionate hydrochloride - Drug Profile 80 MRG-110 - Drug Profile 81 MultiGeneAngio - Drug Profile 82 MultiGeneGraft - Drug Profile 83 O-304 - Drug Profile 84 PC-mAb - Drug Profile 86 PDA-002 - Drug Profile 88 PF-05285401 - Drug Profile 89 REC-03 - Drug Profile 101 Rejuveinix - Drug Profile 102 rivaroxaban - Drug Profile 103 sodium nitrite SR - Drug Profile 119 Stem Cell Therapy for Cardiovascular Disease, Central Nervous System Disorders, Infectious Diseases, Respiratory and Metabolic Disorders - Drug Profile 121 transcrocetinate sodium - Drug Profile 126 TXA-127 - Drug Profile 130 TXA-302 - Drug Profile 134 V-10 - Drug Profile 135 VM-202 - Drug Profile 136 vonapanitase - Drug Profile 140 YY-984 - Drug Profile 146 zibotentan - Drug Profile 147 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 149 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 151 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 152 Featured News & Press Releases 152 Appendix 162 Methodology 162 Coverage 162 Secondary Research 162 Primary Research 162 Expert Panel Validation 162 Contact Us 162 Disclaimer 163
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athera Biotechnologies AB, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by BiogenCell Ltd, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corp, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Foresee Pharmaceuticals LLC, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Ltd, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co Ltd, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by LipimetiX Development Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Novartis AG, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau SpA, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by VESSL Therapeutics Ltd, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co Ltd, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma Inc, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2017 (Contd..1), H1 2017 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
